

Research

Open Access

Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid

Kathryn E Nichol*¹, Wayne W Poon¹, Anna I Parachikova¹,
David H Cribbs^{1,3}, Charles G Glabe^{1,2} and Carl W Cotman^{1,3}

Address: ¹Institute for Brain Aging & Dementia, University of California, Irvine. Irvine, CA, USA, ²Department of Molecular Biology & Biochemistry, University of California, Irvine. Irvine, CA, USA and ³Department of Neurology, University of California, Irvine, CA, USA

Email: Kathryn E Nichol* - knichol@uci.edu; Wayne W Poon - wpoon@uci.edu; Anna I Parachikova - aparachi@uci.edu; David H Cribbs - cribbs@uci.edu; Charles G Glabe - cglabe@uci.edu; Carl W Cotman - cwcotman@uci.edu

* Corresponding author

Published: 9 April 2008

Received: 15 January 2008

Journal of Neuroinflammation 2008, 5:13 doi:10.1186/1742-2094-5-13

Accepted: 9 April 2008

This article is available from: <http://www.jneuroinflammation.com/content/5/1/13>

© 2008 Nichol et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Inflammation is associated with A β pathology in Alzheimer's disease (AD) and transgenic AD models. Previously, it has been demonstrated that chronic stimulation of the immune response induces pro-inflammatory cytokines IL-1 β and TNF- α which contribute to neurodegeneration. However, recent evidence has shown that inducing the adaptive immune response reduces A β pathology and is neuroprotective. Low concentrations of IFN- γ modulate the adaptive immune response by directing microglia to differentiate to antigen presenting cells. Our objective was to determine if exercise could induce a shift from the immune profile in aged (17–19 months) Tg2576 mice to a response that reduces A β pathology.

Methods: TG (n = 29) and WT (n = 27) mice were divided into sedentary (SED) and exercised (RUN) groups. RUN animals were provided an in-cage running wheel for 3 weeks. Tissue was harvested and hippocampus and cortex dissected out. Quantitative data was analyzed using 2 \times 2 ANOVA and student's t-tests.

Results: IL-1 β and TNF- α were significantly greater in hippocampi from sedentary Tg2576 (TG_{SED}) mice than in wildtype (WT_{SED}) (p = 0.04, p = 0.006). Immune response proteins IFN- γ and MIP-1 α are lower in TG_{SED} mice than in WT_{SED} (p = 0.03, p = 0.07). Following three weeks of voluntary wheel running, IL-1 β and TNF- α decreased to levels indistinguishable from WT. Concurrently, IFN- γ and MIP-1 α increased in TG_{RUN}. Increased CD40 and MHCII, markers of antigen presentation, were observed in TG_{RUN} animals compared to TG_{SED}, as well as CD11c staining in and around plaques and vasculature. Additional vascular reactivity observed in TG_{RUN} is consistent with an alternative activation immune pathway, involving perivascular macrophages. Significant decreases in soluble A β ₄₀ (p = 0.01) and soluble fibrillar A β (p = 0.01) were observed in the exercised transgenic animals.

Conclusion: Exercise shifts the immune response from innate to an adaptive or alternative response. This shift in immune response coincides with a decrease in A β in advanced pathological states.

Background

Successful long-term treatment for Alzheimer's disease (AD) has remained as elusive as the disease's cause. Lifestyle treatments for AD, such as exercise, are being researched in both animal and human models [1-5]. Exercise has been found to be a successful preventative measure in delaying disease onset. Exercise interventions in patients who already exhibit AD symptoms have had mixed results, but are able to show improvement to varying degrees [2-5].

The pathology in AD is well-known. A β and tau deposits are the chief pathological hallmarks. A β has been implicated in impairing learning and memory [6-10]. A β deposition stimulates a local immune response by the microglia, which become macrophagic [11-13]. The macrophagic phenotype in AD is characterized by the presence of CD11b and immunohistochemistry revealing attempted phagocytosis of A β [11,14-16]. This response is not sufficient to clear A β deposits and instead contributes to the chronic progression of AD [17-19]. Chronically activated microglia are characterized by their macrophagic morphology, CD11b expression, and release of neurotoxic cytokines IL-1 β and TNF- α [20,21]. This response of microglia seems to contribute to AD progression, rather than clearing A β pathology [22-24].

However, the immune responses possible in the brain are more complex than was once thought. Aside from the initial innate response, characterized by macrophagic microglia and cytokine production, adaptive responses in which antigen is presented to T cells infiltrating from the periphery has been increasingly observed in various neurodegenerative disease states and in A β vaccination studies [14,25-28]. In addition, exciting new evidence exists of an alternative immune response, characterized by perivascular cells that participate in both innate immunity, via phagocytosis and cytokine production, as well as adaptive immunity via antigen presentation and co-stimulation at the blood brain interface [29-31]. Evidence indicates that the AD brain is capable of clearing A β if the microglial response is manipulated [32]. For instance, injected bone marrow cells travel to the brain and differentiate into microglia. These newly differentiated microglia acquire a dendritic, rather than macrophagic phenotype and are associated with antigen presentation and a decrease in A β [32]. Further, microglia stimulated with glatiramer acetate or IFN- γ change phenotype and become antigen presenting cells [33-35]. This antigen presenting phenotype stimulates the adaptive immune response, characterized by increased major histocompatibility complex II (MHCII) expression and CD11c positive cells [34,36]. Butovsky et al. (2007) and Ziv et al (2006) have also shown this shift to the adaptive immune response coincides with decreases in cytokines associated with the innate immune

response, namely IL-1 β and TNF- α [34,37]. The identity of the antigen presenting cells was initially unclear in these studies. However, it has recently been suggested that the clearance of A β is dependent on invasion of the brain by peripheral monocytes, which differentiate into antigen presenting microglia [35,38]. A stimulus to the immune response in late AD may confer benefit through clearance of soluble species of A β , as evidenced in several studies using lipopolysaccharide or A β immunization [39-41]. The role of microglia in AD is clearly complex and can be either detrimental or beneficial, depending on the nature of the microglial response.

While physical exercise can delay the onset of cognitive decline in AD, the mechanisms remain largely unknown [42-46]. Adlard et al. recently demonstrated that exercise reduced A β deposition in AD transgenic mice [1]. We suggest that exercise may be also altering the immune response in AD, which in turn affects A β levels. We hypothesize that the protective effects of exercise in AD may be due in part to an immune shift from innate to antigen presenting, similar to the shift observed by Butovsky et al (2005-2007) [33,35]. Specifically, we hypothesize that this shift is characterized by decreases in markers of the innate response, such as TNF- α and IL-1 β , as well as increases of adaptive and alternative activation response stimulating cytokine IFN- γ . We further suggest that exercise induces a microglial phenotype shift from a macrophagic phenotype to an antigen presenting phenotype, expressing CD11c and MHC II. We also expect to see increased CD40, which communicates from the antigen presenting cell to CD40 ligand on T cells. It is possible this shift in immune response could decrease A β species in the Tg2576 mouse, as seen in the Butovsky studies [33-35,38]. In contrast to Butovsky, our study is unique in that we examined whether physical exercise can induce this immune shift without pharmacological intervention.

In the current study, we used the Tg2576 AD mouse model developed by Karen Hsiao [47]. Tg2576 mice exhibit plaque pathology at 10 months, but show cognitive deficits as early as 6 months [8,48]. For the present study, we were interested in using aged mice with advanced pathology and memory deficits. The older mouse with advanced pathology serves as a model for later stages of AD. We have previously demonstrated that three weeks of voluntary running improved water maze performance in aged (17-19 month) Tg2576 mice [49]. In this investigation, we examine a shift in the immune response to A β as a potential mechanism for the behavioral improvements.

Methods

Animals

The University of California, Irvine's Institutional Care and Use Committee approved all animal protocols. We used C57Bl6/SJL (WT) and Tg2576 (TG) from an established colony (ca. 2000) at University of California, Irvine. We assigned Tg2576 (n = 29) and C57Bl6/SJL (n = 27) to cages containing exercise wheels (RUN) or size matched cages without wheels (SED) at 16–18 months of age, singly-housed. We provided RUN animals with running wheels for 3 weeks and monitored their running via software (Minimitter).

We sacrificed RUN animals along with SED animals by decapitation. We then dissected hippocampi and cortices in physiological saline solution (145 mM NaCl, 4.7 mM KCl, 2 mM CaCl₂, 1 mM MgSO₄, 4 mM MOPS, 1 mM NaH₂PO₄, 5 mM glucose, 2 mM pyruvic acid, 20 μM EDTA; pH 7.4), placed in microfuge tubes on dry ice, and stored frozen at -80°C. Frozen tissue was prepared by pulverization on dry ice. Pulverized tissue was sonicated in cell lysis buffer (Bio-Rad) according to Hulse et al. [50]. Protein content determined by bichondruric acid method (Bio-Rad, Hercules, CA).

Cytokines

Bio-plex multi-plex analysis (Bio-Rad, # X600063YDF) was performed according to manufacturer's instructions in a custom kit designed to detect multiple cytokines. The bio-plex technology uses polystyrene beads internally dyed with differing ratios of two spectrally distinct fluorophores. Dyed beads are labeled with antibodies for each cytokine and the antibody-conjugated beads are allowed to react with sample and a secondary antibody in a 96-well plate to form a capture sandwich immunoassay. The assay solution is read by a Bio-Plex array reader, which distinguishes the beads' spectral address. Using the amount of green fluorescence emitted by the phycoerythrin-tagged detection antibody, the array reader extrapolates the concentration to the appropriate standard curve. Multiplex technology allows us to look at many cytokines within a single sample of tissue. We performed bio-plex analysis on 24 animals (n = 6 per group). We validated bio-plex findings for IFN-γ (BD Biosciences) and TNF-α (BD Biosciences) by ELISA. Because IL-1β levels were below detection sensitivity of the bio-plex assay, we also performed an ELISA for IL-1β, using this data in statistical analysis (Pierce).

Western blot

IFN-γ activates an antigen presenting phenotype in microglia [34]. To further examine antigen presenting cell activity suggested by the cytokine profile observed in TG_{RUN} vs. TG_{SED}, we examined CD40 and MHC II protein expression in the hippocampus via western blot. For CD40

detection, 15 μg of hippocampal lysates from a randomly selected subset of animals (n = 8 TG_{RUN}, n = 7 TG_{SED}, n = 4 WT_{RUN}, n = 9 WT_{SED}) were prepared. Samples were prepared in loading buffer and boiled 5 minutes, then electrophoresed on 10% Tris-HCl ready-made gels (Bio-Rad) along with a homogenized liver sample as a positive control. Proteins were transferred to PVDF membrane overnight at 4°C. We blocked the membranes for 2 hours in StartingBlock™ PBS buffer (Pierce). We incubated membranes overnight at 4°C in 1:200 CD40 monoclonal antibody (BD Pharmingen, #550285) washed, and incubated in HRP-conjugated secondary anti-rat antibody (Santa Cruz, #sc-2065) 2 hours at 1:5000 in tris buffered saline with 1% Tween-20. We washed the membranes extensively, then used West Pico chemiluminescence to detect antigens. Results were visualized on Pierce CL-Xposure™ blue film. Results were quantified using Image J freeware as percent reactivity of CD40/β-actin (AbCam) and t-tests between WT_{SED} and TG_{SED}, as well as TG_{SED} and TG_{RUN} were performed.

Blots for MHC-II (1:100 BD-Pharmingen, #553538) were run on TG_{SED} (n = 8) and TG_{RUN} (n = 8) following the same procedure, using HRP-conjugated donkey anti-rabbit secondary antibody (1:1000, Jackson). Densitometric values for MHC II were normalized to β-actin (1:1000, SIGMA). Iba-1 (WAKO) was also used (1:2000) to probe the membranes for general microglia reactivity using the same basic paradigm. Iba-1 was quantified relative to β-actin.

Aβ ELISA

It is not clear if an increase in adaptive immunity in the hippocampus would lead to changes in levels of the pathological hallmark of AD, Aβ, in animals of such advanced age. Cortical samples from TG_{SED} (n = 5) and TG_{RUN} (n = 6) were pulverized and then sonicated in T-PER buffer (PIERCE) (10 μl/mg tissue). Samples were centrifuged for one hour at 100,000 g. Supernatant was removed and saved as the soluble fraction at -80°C. The insoluble fraction was resuspended in 70% formic acid and sonicated. It was then spun a second time at 100,000 g for one hour and the formic acid layer (middle layer) removed and stored at -80°C.

Brain samples were run in triplicate on 96-well Immulon 2-HB plates (Thermo Electron Corp., Milford, MA) coated with a monoclonal anti-Aβ₁₋₁₆ antibody at 25 ug/ml (kindly provided by Dr. William Van Nostrand, Stony Brook University, Stony Brook, NY) and detection was by monoclonal HRP-conjugated antibodies anti-Aβ₁₋₄₀ at 1:500 (MM32-13.1.1) and anti-Aβ₁₋₄₂ at 1:1000 (MM40-21.3.1) (kindly provided by Dr. Christopher Eckman, Mayo Clinic Jacksonville, Jacksonville, CA). Detection antibodies were visualized using the HRP-substrate 1-Step

Ultra TMB-ELISA buffer (Pierce, Rockford, IL). For standards, synthetic A β ₁₋₄₀ and A β ₁₋₄₂ (Bachem California, Inc., Torrance, CA) were used after a pretreatment with HFIP to prevent fibril formation. Synthetic A β ₁₋₄₀ or A β ₁₋₄₂ were prepared in the same buffer as the samples and A β values were determined by comparison to the appropriate standard curve. The inclusion of a series of controls to test the absorbance of buffers, samples, and both capture and detection antibodies yielded negative results.

A β dot blots & multiplex

A β species were quantified by dot-blot analysis. Hippocampal lysates were prepared from TG_{SED} (n = 5) and TG_{RUN} (n = 5) as described [8]. Wildtype samples (n = 2) were used as negative controls. Protein concentrations were determined by BCA (Pierce). An equal amount of protein from each sample was spotted onto nitrocellulose membranes (Schleicher and Schuell, 0.2 micron) and membranes were blocked 90 minutes at room temperature and incubated with appropriate primary antibodies (6E10 Covance, Princeton, NJ) and OC (kindly provided by Charles Glabe) 60 min at room temperature. These antibodies were used to assess total and fibrillar oligomeric A β , respectively. The OC antibody is conformation specific (for a more detailed description, see Kaye et al, 2007) [51]. Membranes were then washed, incubated with appropriate HRP-conjugated secondary (EMD Chemicals, San Diego, CA) and visualized by ECL (Super-signal West Pico, Pierce). Films were scanned and amyloid levels were quantitated using NIH Image J Software.

Aggregated A β was also measured in the aforementioned hippocampal samples and serum samples using multiplex technology and the human aggregated beta amyloid kit from Biosource/Invitrogen (catalog #LHB3491). The antibodies contained in this kit are specific for the 12 subunit oligomeric form of A β (also known as Amyloid Derived Diffusible Ligand, ADDL, A β *)

Immunohistochemistry

A small number of animals (n = 4 TG_{SED}, n = 4 TG_{RUN}, n = 4 WT_{SED}, n = 4 WT_{RUN}) were perfused with paraformaldehyde and brains dissected for immunohistochemistry for general microglia (CD11b) and dendritic (CD11c) microglial markers colocalized with A β (CD11b, BD Pharmingen; CD11c, Antigenix; A β , 6E10, Covance). Macrophagic markers CD68 (DAKO) and perivascular

macrophage marker mannose receptor (HyCult Biotechnology) were used to identify macrophages and their relationship to CD11c+ cells and/or Iba-1 + microglia.

Results


No significant differences in running distances existed between genotypes. (Table 1)

IL-1 β and TNF- α protein were significantly greater in aged sedentary Tg2576 mice (TG_{SED}) than in sedentary wildtype (WT_{SED}) (IL-1 β : p = 0.006; TNF- α : p = 0.04) (Figure 1). Three weeks of exercise decreased the levels of both IL-1 β and TNF- α to a point where they no longer significantly differed from the WT_{SED}. The IL-1 β in exercised Tg2576 mice (TG_{RUN}) was significantly lower than in the TG_{SED} (p = 0.01)(Figure 1). When we compare current cytokine markers to our previously published behavioral data, the decreased levels of the pro-inflammatory cytokine IL-1 β observed in transgenic animals correlate with decreased mean latency to find the escape platform on day 2 of the radial arm version of the Morris water maze (correlation = 0.31, p = 0.001)[49]. We observed CD11b+ microglia in TG_{SED} and TG_{RUN} animals (Figure 2). Levels of microglial activation, as measured by Iba-1 western blot, did not change with exercise (Figure 2).

In contrast, IFN- γ was significantly lower in aged TG_{SED} than in WT_{SED} (p = 0.02) and showed a trend to increase in TG_{RUN} (p = 0.06) such that it returned to levels similar to the WT (Figure 3). Similarly, protein levels of chemokine MIP1 α that tended to be lower in the TG_{SED} than the WT_{SED} (p = 0.07), were significantly increased in TG_{RUN} animals (p = 0.05) to levels similar to those observed in the WT (Figure 3). The MHC II blots confirm that the IFN- γ increase observed is associated with increased antigen presentation in the TG_{RUN} animals, who expressed significantly more MHC II than TG_{SED} (p = 0.04) (Figure 4). In the TG_{RUN} animals, we observed abundant antigen presenting cells, indicated by CD11c (Figure 5B). In TG_{RUN} we observed CD11c+ blood vessels and in individual cells that appeared linearly arranged, as if inside of blood vessels (Figure 5B,C). Vessels labeled strikingly with CD68 (red) in proximity to, but not within the same cells as CD11c (green), suggesting alternatively activated macrophages may be present (Figure 5D-F). Vessels were double labeled for Iba-1 (green) and mannose receptor (red), a marker for perivascular macrophages (Figure 5G-I). No

Table 1: Swim speeds and wheel rotations. Swim speeds did not significantly differ between any groups. Number of wheel rotations per day did not differ between genotypes.

	WTSED	WTRUN	TGSED	TGRUN
Swim speed (m/s)	0.15 \pm 0.02	0.16 \pm 0.03	0.11 \pm 0.03	0.18 \pm 0.03
Wheel rotations/day	n/a	4408 \pm 783	n/a	3954 \pm 877

**Figure 1**

IL-1 β is significantly greater in sedentary Tg2576 mice than in WT sedentary mice ($p = 0.006$). Exercise results in a significantly lower level of IL-1 β in the Tg2576 ($p = 0.01$). The level of IL-1 β in exercised Tg2576 mice (TG_{RUN}) is no longer distinguishable from the WT mouse (WT_{SED}). TNF- α is significantly greater in sedentary Tg2576 mice (TG sed) than in WT sedentary mice ($p = 0.04$). Exercise reduces TNF- α in TG mice (TG run) to a level indistinguishable from the WT (WT_{SED}). *Significantly different from sedentary WT † significantly different from sedentary Tg2576.




Figure 2

CD11b positive microglia (green immunofluorescence) in TG_{SED}(A). Higher magnification reveals some co-labeling with microglial marker Iba-1 (red) (B, arrowheads). CD11b positive glia are present in TG_{RUN} (C) and co-labeled with Iba-1 (red) in some cases (D, arrowheads). Overall levels of Iba-1 (normalized to actin) are not significantly different based on condition or genotype (E). High immunoreactivity for Iba-1 in WT is likely due to the advanced age of the animals used.





Figure 3

IFN- γ is significantly lower in the Tg2576 sedentary mice than in the WT sedentary mice ($p = 0.03$). Exercise resulted in increased levels of IFN- γ in the Tg2576 mouse (TG_{RUN}) to a level indistinguishable from the WT (WT). MIP-1 α demonstrated a trend of being lower in TG_{SED} compared to the WT ($p = 0.07$), but was significantly increased by exercise (TG_{RUN}) ($p = 0.05$). *Significantly different from sedentary WT; † significantly different from sedentary Tg2576.

MHCII



CD40




Figure 4

MHC II levels were significantly greater in TG_{RUN} than TG_{SED} ($p = 0.04$). CD40 is significantly greater in TG_{RUN} compared to TG_{SED} ($p = 0.008$). WT_{SED} tended to have greater levels of CD40 than TG_{SED}, but this difference failed to achieve significance ($p = 0.10$). † Significantly different from sedentary Tg2576.




Figure 5

CD11c positive microglia (green immunofluorescence) are present in TG_{SED} and colocalize with Iba-1 (arrowheads) but do not appear vascular (A). CD11c labeling in TG_{RUN} appeared in cells not labeled by Iba-1 (red) that were linearly arranged, perhaps within or around microvessels. (B, D). Larger vessels had CD11c labeling along the vessel wall, perhaps in the perivascular space (C). Using macrophage markers CD68, we observed microvascular labeling again only in TG_{RUN} (D). Double labeling for CD11c (green) and CD68 (red) revealed that CD11c⁺ cells were adjacent to CD68⁺ cells in and around vasculature (arrows) (E, F). Using mannose receptor antibody (red), specific for perivascular macrophages, we again observed vascular labeling only in TG_{RUN} (G-I). High magnification shows the mannose receptor labeled cells are within vessels (H, I)(arrowheads). Green indicates Iba-1 labeling for microglia in and around vessels (G-I).

such cells or vessels were observed using the same markers in TG_{SED} animals.

The presence of MHCII and CD11c labeled cells indicate antigen presentation. Increased MIP-1 α levels suggest T cells and monocytes are being recruited to the brain (Man, 2007). CD40, expressed by the antigen presenting cell communicates with its ligand on T cells. In sedentary TG animals, a trend of reduced expression of CD40 is present compared to WTSED ($p = 0.10$), but there is a significant elevation in CD40 from TG_{SED} to TGRUN ($p = 0.008$) (Figure 4). Additionally, alternative activation of macrophages could explain the shift in immune markers observed [29]. Indeed, if we consider all of the cytokine and chemokine changes collectively, along with the conflicting reports of T cell presence and function in the brain [27], alternative activation of macrophages may be a more likely candidate for repair in an AD state [52].

Finally, we examined whether exercise leads to reduced A β in aged Tg2576 mice. We quantified the levels of various A β species in cortex by ELISA, and in hippocampus and serum using multiplex technology as well as dot blot. Multiplex revealed no statistically significant differences in A β aggregates in hippocampus, though direction of change was to decrease in run (Figure 6A). There was no detectable aggregated A β in the serum samples and immunohistochemical staining for plaques appeared similar between TG_{SED} and TG_{RUN} (data not shown). ELISA of A β_{42} in soluble and insoluble fractions from cortex did not statistically differ between TG_{SED} and TG_{RUN} though we should note that there was a large degree of variation between the RUN animals (Figure 6B–C) Total soluble levels of A β_{40} did show a significant decrease ($p = 0.01$) in the TG_{RUN} animals compared to the TG_{SED} (Figure 6B). Soluble A β is composed of both fibrillar and pre-fibrillar oligomeric species[51]. We used a conformation specific fibrillar antibody to explore changes with exercise in the Tg2576 [39].

The dot blots of hippocampal lysates are able to selectively probe different soluble A β species in a soluble fraction, spun at low speeds. First, we analyzed total A β using 6E10 on dot blots. We did not detect any significant differences between SED and RUN (Figure 7A). The OC antibody detects soluble fibrillar A β that is conformationally and immunologically distinct [51]. Levels of soluble A β fibrils were 40% lower in TG_{RUN} compared to TG_{SED} as assessed by OC antibody (Figure 7B). This decrease was significant ($p = 0.01$).

Discussion

We have demonstrated that physical exercise can shift the immune response in the brain of an AD mouse model. AD is characterized by an innate immune response character-

ized by microglial activation. Though likely an intended protective mechanism to phagocytose A β , these glia are not capable of combating chronic AD pathology [53]. In addition, the cytokines released by these microglia, IL-1 β and TNF- α , become cytotoxic when chronically expressed, contributing to the overall neurodegeneration [20,21,24,35,54-56]. We confirmed this immune state in our sedentary aged TG animals. Our findings confirm previous findings that high IL-1 β levels are correlated with poor cognitive performance [57] and indicate that exercise induces reductions in TNF- α and IL-1 β in the hippocampus of Tg2576 mouse at advanced age.

Recent investigations into bone marrow derived cells that differentiate into microglia in the brain, in concert with studies where microglial phenotype is experimentally altered to an antigen presenting phenotype collectively suggest that if the adaptive immune response is stimulated, A β pathology in AD can be reduced and cognition improved [58,59,34,35,38]. The antigen presenting response is characterized by CD11c positive cells, MHC II, and CD40. IFN- γ has been shown to be a stimulus for this microglial phenotype and has also been found to be capable of inducing A β clearance [37]. We demonstrate that the aged TG_{SED} mouse express lower levels of IFN- γ than the WT and that exercise results in increased IFN- γ and increased markers of the antigen presenting response. In addition to antigen presenting microglia from the local environment, it is also possible that exercise increases recruitment of peripheral monocytes to the brain, where they too can become antigen presenting cells. MIP-1 α recruits central and/or peripheral macrophages to the area of plaque deposition in AD and MIP-1 α was found to increase in TG_{RUN}[60,61]. However, the possibility of peripheral recruitment is in debate, as recent data indicates that much of the evidence in favor of monocyte recruitment to the brain only occurs in the presence of damage to the blood-brain barrier due to the whole-body irradiation used in the original experiments [38,59,62-64]. The integrity of the blood brain barrier is compromised in AD and in the Tg2576 mouse model, however, so we cannot rule out either a peripheral or central source for these microglia [65-67]. Though the origin or the microglia will be a topic for continued investigation, we do demonstrate that the microglia present in the hippocampus after exercise in the aged TG mice exhibit characteristics of the adaptive immune response and antigen presentation.

Another interesting possibility presented by the vascular localization of macrophagic markers observed in TG_{RUN} animals is the alternative activation of perivascular cells as macrophages and antigen presenting cells. Though microglia are the initial immune responders in the CNS, perivascular cells may be more efficient at both phagocy-




Figure 6
 Aβ analysis by multiplex and ELISA. Aggregated Aβ levels are not significantly lower in hippocampus of TG_{RUN} compared to TG_{SED}, though a 35% decrease is observed in means. (A) Aβ₄₀ but not Aβ₄₂ is significantly lower in soluble fractions from cortex of TG_{RUN} and TG_{SED} (p = 0.01)(B). There are no significant differences in insoluble fractions (C).




Figure 7

Aβ analysis by dot blot. No differences existed between TG_{SED} and TG_{RUN} for total Aβ in the soluble fraction of hippocampal samples, evaluated by 6E10 antibody (A). Aβ fibrils, detected by OC antibody, were significantly decreased in TG_{RUN} animals compared to TG_{SED} (p = 0.01)(B). A representative dot blot is shown (C).

tosis of antigen and presentation of that antigen than adult microglia [25,68]. In particular, our data revealing extensive mannose receptor labeling in TG_{RUN} animals strongly indicates perivascular macrophages are involved in the immune response, as this receptor is not expressed by microglia [31].

We suggest that the antigen being presented is Aβ or an Aβ fragment. Fibrillar Aβ is a highly cytotoxic species that has been shown to adhere to microglia [69,70]. If microglia are stimulated to take on an antigen presenting phenotype, fibrillar Aβ can be cleared from the brain [53]. In the

current study, soluble Aβ₄₀ and soluble fibrillar Aβ significantly decreased after three weeks of running coincident with the increase in adaptive immune markers and the improvement in behavior [49]. We also observed CD11c adjacent to mannose receptor and CD68 positive cells within the vasculature of TG_{RUN}. This presence of perivascular macrophages in conjunction with markers of antigen presentation might be indicative of clearance of Aβ into the periphery, supporting the "peripheral sink" hypothesis, in which Aβ is proposed to efflux from brain into plasma after immunization therapy [71-73]. Indeed, one proposed function of the mannose receptor which we

observed in TG_{RUN} is antigen transport [31]. Vasilevko et al. (2007) recently showed that direct immunotherapy with anti-A β antibodies resulted in decreased diffuse A β deposits in brain, but increased A β ₄₀ in plasma [40].

In this study, we present evidence that exercise decreases the chronic pro-inflammatory response well known to associate with AD. The decrease in at least one of the cytokines, IL-1 β , correlates with improved ability to solve a water maze task. Unlike ibuprofen and other anti-inflammatory drugs used in AD treatment, which decrease pro-inflammatory markers, the current study provides evidence that exercise not only decreases pro-inflammatory markers like IL-1 β and TNF- α , but also increases adaptive inflammatory markers IFN- γ , CD40, MHC II, CD11c, and MIP-1 α . We observed multiple macrophage markers (CD68, mannose receptor) in and around the vasculature of TG_{RUN} animals. Further, we have shown that exercise decreases soluble A β ₄₀ and soluble fibrillar A β . We support the hypothesis put forward by Butovsky et al (2006) that the innate immune response in AD becomes dysfunctional after chronic activation, but that an initiation of the adaptive or alternative immune response may reduce pathology [35]. The decrease in fibrillar A β and improvement in behavior observed in our investigations of the Tg2576 mouse at 17–19 months of age suggests that physical exercise can trigger this immune shift in late stages of AD, leading to cognitive improvement [49].

Conclusion

Our data suggests that exercise intervention may pave the way for successful A β clearance even in late stages of AD. We suggest that exercise not only decreases neurotoxic cytokines, but also increases A β clearance through its induction of an adaptive or alternative immune response. In summary, our investigation opens a potential avenue for behavioral interventions that would be complementary to long term NSAIDs or anti-inflammatory drugs.

List of abbreviations

WT: Wildtype; TG: Transgenic; SED: Sedentary; AD: Alzheimer's disease; IL: Interleukin; TNF: Tumor necrosis factor; MHC: Major histocompatibility complex; IFN: Interferon; MIP: Macrophage inflammatory protein; CNS: Central nervous system; NSAIDs: Non-steroidal anti-inflammatory drugs.

Competing interests

CGG is a consultant for Kinexis, Inc. The remaining authors declare that they have no competing interests.

Authors' contributions

KEN designed and implemented the investigation and was responsible for data analysis, interpretation, and preparation of the manuscript. WWP performed the for

A β dot blots. AIP aided in study design and preparation of tissue for histology. DHC provided A β ELISA data and contributed to the direction of the investigation and data interpretation. CGG created the unique antibodies used to assess A β in the dot blot analysis. CWC contributed to the writing of the manuscript and the data interpretation.

Acknowledgements

The authors would like to thank Hyun Jin Kim and Dr. Vitaly Vasilevko for assisting with the A β ELISAs. We wish to acknowledge Mr. Rick Muth for his generous support and Mary Brodey of Invitrogen for supplying the A β aggregate kits. We thank NIAMSD and NIA for their supporting grants AR047752 and AG000538

References

- Adlard PA, Perreau VM, Pop V, Cotman CW: **Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease.** *J Neurosci* 2005, **25(17)**:4217-4221.
- Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR, Fleshner MR, Gandevia SC, Gomez-Pinilla F, Greenwood BN, Hillman CH, Kramer AF, Levin BE, Moran TH, Russo-Neustadt AA, Salamone JD, Van Hoomissen JD, Wade CE, York DA, Zigmond MJ: **Neurobiology of exercise.** *Obesity (Silver Spring)* 2006, **14(3)**:345-356.
- Etnier JL, Caselli RJ, Reiman EM, Alexander GE, Sibley BA, Tessier D, McLemore EC: **Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness.** *Med Sci Sports Exerc* 2007, **39(1)**:199-207.
- Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, Kukull WA, LaCroix AZ, McCormick W, Larson EB: **Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial.** *Jama* 2003, **290(15)**:2015-2022.
- Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W: **Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.** *Ann Intern Med* 2006, **144(2)**:73-81.
- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: **Naturally secreted oligomers of amyloid beta protein potentially inhibit hippocampal long-term potentiation in vivo.** *Nature* 2002, **416(6880)**:535-539.
- Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: **Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.** *J Neurosci* 2004, **24(15)**:3801-3809.
- Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH: **A specific amyloid-beta protein assembly in the brain impairs memory.** *Nature* 2006, **440(7082)**:352-357.
- Kim SH, Tang YP, Sisodia SS: **Abeta star: a light onto synaptic dysfunction?** *Nat Med* 2006, **12(7)**:760-1; discussion 761.
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: **Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.** *Proc Natl Acad Sci U S A* 1998, **95(11)**:6448-6453.
- Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F: **Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway.** *Neurobiol Dis* 2002, **11(2)**:257-274.
- Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J: **Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice.** *J Neuroimmunol* 2002, **126(1-2)**:50-57.
- Dudal S, Morissette C, Lacombe D, Tremblay P, Gervais F: **Differences in the amyloid-beta-induced inflammatory response in microglia from C57BL/6 and A/J strains of mice.** *J Neuroimmunol* 2004, **153(1-2)**:26-35.
- Monsonogo A, Imitola J, Zota V, Oida T, Weiner HL: **Microglia-mediated nitric oxide cytotoxicity of T cells following amy-**

- loid beta-peptide presentation to Th1 cells. *J Immunol* 2003, **171**(5):2216-2224.
15. Koenigsnecht J, Landreth G: **Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism.** *J Neurosci* 2004, **24**(44):9838-9846.
 16. Sheng JG, Mrak RE, Griffin WS: **Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms.** *Acta Neuropathol* 1997, **94**(1):1-5.
 17. Fiala M, Cribbs DH, Rosenthal M, Bernard G: **Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease.** *J Alzheimers Dis* 2007, **11**(4):457-463.
 18. Streit WJ: **Microglial senescence: does the brain's immune system have an expiration date?** *Trends Neurosci* 2006, **29**(9):506-510.
 19. Streit WJ: **Microglia as neuroprotective, immunocompetent cells of the CNS.** *Glia* 2002, **40**(2):133-139.
 20. Wyss-Coray T: **Inflammation in Alzheimer disease: driving force, bystander or beneficial response?** *Nat Med* 2006, **12**(9):1005-1015.
 21. Griffin WS: **Inflammation and neurodegenerative diseases.** *Am J Clin Nutr* 2006, **83**(2):470S-474S.
 22. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW: **Interleukin-1 mediates Alzheimer and Lewy body pathologies.** *J Neuroinflammation* 2006, **3**:5.
 23. Mrak RE, Griffin WS: **Glia and their cytokines in progression of neurodegeneration.** *Neurobiol Aging* 2005, **26**(3):349-354.
 24. Streit WJ, Mrak RE, Griffin WS: **Microglia and neuroinflammation: a pathological perspective.** *J Neuroinflammation* 2004, **1**(1):14.
 25. Aloisi F, Ria F, Adorini L: **Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes.** *Immunol Today* 2000, **21**(3):141-147.
 26. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW: **Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice.** *Neurobiol Dis* 2006, **23**(2):351-361.
 27. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH: **Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease.** *Neurobiol Aging* 2007, **28**(4):485-496.
 28. Monsonogo A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL: **Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.** *Proc Natl Acad Sci U S A* 2006, **103**(13):5048-5053.
 29. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS: **CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.** *Proc Natl Acad Sci U S A* 2007, **104**(49):19446-19451.
 30. Kim WK, Alvarez X, Fisher J, Bronfin B, Westmoreland S, McLaurin J, Williams K: **CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood.** *Am J Pathol* 2006, **168**(3):822-834.
 31. Galea I, Palin K, Newman TA, Van Rooijen N, Perry VH, Boche D: **Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain.** *Glia* 2005, **49**(3):375-384.
 32. Simard AR, Rivest S: **Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease.** *Mol Psychiatry* 2006, **11**(4):327-335.
 33. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M: **Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective.** *Mol Cell Neurosci* 2005, **29**(3):381-393.
 34. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M: **Microglia can be induced by IFN-gamma or IL-4 to express neural or dendritic-like markers.** *Mol Cell Neurosci* 2007, **35**(3):490-500.
 35. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M: **Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor I.** *Proc Natl Acad Sci U S A* 2006, **103**(31):11784-11789.
 36. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G, Schwartz M: **Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells.** *Mol Cell Neurosci* 2006, **31**(1):149-160.
 37. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, Cohen H, Kipnis J, Schwartz M: **Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood.** *Nat Neurosci* 2006, **9**(2):268-275.
 38. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M: **Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model.** *Eur J Neurosci* 2007, **26**(2):413-416.
 39. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN: **Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice.** *J Neuroimmune Pharmacol* 2007, **2**(2):222-231.
 40. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH: **Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice.** *J Neurosci* 2007, **27**(49):13376-13383.
 41. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D: **Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice.** *Neurobiol Aging* 2001, **22**(6):1007-1012.
 42. Churchill JD, Galvez R, Colcombe S, Swain RA, Kramer AF, Greenough WT: **Exercise, experience and the aging brain.** *Neurobiol Aging* 2002, **23**(5):941-955.
 43. Cotman CW, Berchtold NC: **Exercise: a behavioral intervention to enhance brain health and plasticity.** *Trends Neurosci* 2002, **25**(6):295-301.
 44. Scarmeas N, Stern Y: **Cognitive reserve and lifestyle.** *J Clin Exp Neuropsychol* 2003, **25**(5):625-633.
 45. Colcombe SJ, Kramer AF, Erickson KI, Scaif P, McAuley E, Cohen NJ, Webb A, Jerome GJ, Marquez DX, Elavsky S: **Cardiovascular fitness, cortical plasticity, and aging.** *Proc Natl Acad Sci U S A* 2004, **101**(9):3316-3321.
 46. McAuley E, Kramer AF, Colcombe SJ: **Cardiovascular fitness and neurocognitive function in older adults: a brief review.** *Brain Behav Immun* 2004, **18**(3):214-220.
 47. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: **Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments].** *Science* 1996, **274**(5284):99-102.
 48. Arendash GW, King DL: **Intra- and intertask relationships in a behavioral test battery given to Tg2576 transgenic mice and controls.** *Physiol Behav* 2002, **75**(5):643-652.
 49. Nichol KE, Parachikova AI, Cotman CW: **Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse.** *Behav Brain Res* 2007, **184**(2):124-132.
 50. Hulse RE, Kunkler PE, Fedynshyn JP, Kraig RP: **Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue.** *J Neurosci Methods* 2004, **136**(1):87-98.
 51. Kaye R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG: **Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers.** *Mol Neurodegener* 2007, **2**(1):18.
 52. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP: **Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.** *J Neuroinflammation* 2006, **3**:27.
 53. Frenkel D, Maron R, Burt DS, Weiner HL: **Nasal vaccination with a proteasome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.** *J Clin Invest* 2005, **115**(9):2423-2433.
 54. Streit WJ: **Microglia and neuroprotection: implications for Alzheimer's disease.** *Brain Res Brain Res Rev* 2005, **48**(2):234-239.
 55. Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL: **Role of microglia in the central nervous system's immune response.** *Neurol Res* 2005, **27**(7):685-691.
 56. Griffin WS, Mrak RE: **Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease.** *J Leukoc Biol* 2002, **72**(2):233-238.

57. Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM: **A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.** *J Neuroinflammation* 2007, **4**:21.
58. Simard AR, Rivest S: **[Bone marrow stem cells to the rescue of Alzheimer's disease].** *Med Sci (Paris)* 2006, **22(10)**:822-824.
59. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: **Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.** *Neuron* 2006, **49(4)**:489-502.
60. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE: **Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model.** *Mol Med* 1998, **4(7)**:480-489.
61. Fiala M, Liu QN, Sayre J, Pop V, Brahmamdam V, Graves MC, Vinters HV: **Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier.** *Eur J Clin Invest* 2002, **32(5)**:360-371.
62. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M: **Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions.** *Nat Neurosci* 2007, **10(12)**:1544-1553.
63. Ajami B, Bennett JL, Kriegler C, Tetzlaff VV, Rossi FM: **Local self-renewal can sustain CNS microglia maintenance and function throughout adult life.** *Nat Neurosci* 2007, **10(12)**:1538-1543.
64. Simard AR, Rivest S: **Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia.** *Faseb J* 2004, **18(9)**:998-1000.
65. Paul J, Strickland S, Melchor JP: **Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.** *J Exp Med* 2007, **204(8)**:1999-2008.
66. Algotsson A, Winblad B: **The integrity of the blood-brain barrier in Alzheimer's disease.** *Acta Neurol Scand* 2007, **115(6)**:403-408.
67. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF: **Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.** *Neurology* 2007, **68(21)**:1809-1814.
68. Floden AM, Combs CK: **Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner.** *J Neurosci* 2006, **26(17)**:4644-4648.
69. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: **Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils.** *Nature* 1996, **382(6593)**:716-719.
70. El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC: **Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease.** *Neurobiol Aging* 1998, **19(1 Suppl)**:S81-4.
71. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: **Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.** *Science* 2002, **295(5563)**:2264-2267.
72. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM: **Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.** *J Neurochem* 2002, **81(2)**:229-236.
73. Lanz TA, Schachter JB: **Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies.** *J Neurosci Methods* 2007.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

